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ABSTRACT 
 
 Osteoarthritis (OA) is the 2nd leading cause of long term disability in North 
America affecting 40 million Americans.  The work presented in this manuscript 
addresses clinical outcome measures used to determine treatment effect and 2 in vitro 
studies using tissue engineering techniques to grow cartilage suitable for in vivo use.  In 
the first study, radiographs of the stifle joint in dogs were scored for the severity of OA, 
and limb function was measured by force platform gait analysis.  The 2 outcome 
measures were analyzed using regression methods.  There was no correlation of the 
severity of radiographic OA and limb function; therefore, radiographs should not be used 
as a measure of functional outcome for the treatment of OA.  Additionally, treatment for 
OA using tissue engineered tissue is a current research paradigm.  The second study in 
the manuscript hypothesized that tantalum trabecular metal was chondroconductive.  
Canine chondrocytes were cultured in vitro under dynamic conditions.  Histopathologic 
evaluation showed matrix stained with toluidine blue and safranin O.  Biochemical 
evaluation of the exterior portion of cartilage showed 84% type II collagen.  The results 
reflected the chondroconductive potential of the unique metal.  In order to optimize the 
medium used for in vitro cartilage production, a pellet culture model was used to 
determine the effect of Fibroblast Growth Factor 2 (FGF2) followed by Transforming 
Growth Factor β1 (TGFβ1) on matrix production.  Although TGFβ1 treated cultures were 
larger than the others, FGF2 treatment in monolayer decreased matrix production.  
Additionally, type II collagen was insufficient in all groups.  Further study is needed to 
define the ideal culture requirements to produce cartilage from canine chondrocytes 
consistently with ideal matrix properties. 
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CHAPTER 1. INTRODUCTION 
 
INTRODUCTION 
 
Osteoarthritis (OA) affects 40,000,000 Americans, is the second most common 
cause for long term disability, and is expected to affect 18.2% of the population by 2020.1  
Similarly, 20% of the canine pet population show clinical signs of OA, and OA is the 
leading cause of euthanasia in military working dogs.2,3,4  Regardless of species, 
osteoarthritis is caused by a disturbance in the homeostasis of normal cartilage.  This 
interruption to homeostasis can be caused by trauma, joint instability, infectious or 
noninfectious inflammation or focal or generalized malformation of the articular surface.  
The pathogenesis of OA is complicated affecting multiple tissues and responses to injury.  
A cascade of inflammatory mediators and other factors affect the subchondral bone, 
cartilage surface, and synovial membrane.  The disease is perpetuated over time causing 
degeneration of the joint and subsequent pain. 
Clinically, radiographs are commonly used in both human and veterinary 
medicine to diagnose and monitor OA.  Unfortunately, radiographic signs of disease are 
nonspecific (e.g. showing osteophytes), lack in sensitivity because they do not evaluate 
cartilage and may lag behind the progression or initiation of OA.  Nonetheless, 
radiography is used as an outcome measure to distinguish between treatment modalities.   
Treatment of OA can be frustrating and end in ultimate failure.  The current 
research paradigm for development of new treatment methodologies includes cartilage 
tissue engineering for joint resurfacing.  The premise for using tissue engineered cartilage 
for treating OA includes replacing damaged cartilage or biomechanically inferior repair 
tissue with either the building blocks for in vivo repair or in vitro generated normal 
cartilage.   
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THESIS ORGANIZATION 
 
 This dissertation addresses both the clinical and the basic sciences of OA.  
Chapters are 2-4 are organized as journal articles with an abstract, introduction, materials 
and methods, results, and discussion.  The reproduction of this material in this thesis is 
done with permission from the publisher.   
Chapter 2 of this thesis investigates the correlation between radiography and the 
function of osteoarthritic limbs.  This study is published in Veterinary Surgery with 
permission from the publisher.  The first author is the graduate student and primary 
author followed by the associate professor and those that contributed to data collection or 
statistical analysis. 
Chapter 3 focuses on the properties of a metal with a unique surface as a scaffold 
for engineering articular cartilage.  This is the first step in developing a cartilage based 
implant capable of replacing the joint surface.  This study has also been published in 
Journal of Biomedical Materials Research Part B: Applied Biomaterials.  The first 
author is the graduate student and primary author followed by the associate professor and 
those that provided collaboration making the project possible. 
In addition to the importance of scaffolds, growth factors are imperative to 
develop mature, healthy, biomechanically stable cartilage.  Chapter 4 investigates the best 
growth factors for extracellular matrix production using canine chondrocytes.  The first 
author is the graduate student and primary author followed by those that contributed to 
the design of the experiment.  The major professor is the last author. 
 
LITERATURE REVIEW 
 
Osteoarthritis 
Articular or hyaline cartilage is the tissue that lines the joint surface.  It is a 
connective tissue with low cellularity made up of predominantly type II collagen, 
glycosaminoglycans, and proteoglycans.  These unique molecules give articular cartilage 
the mechanical properties necessary to support joint range of motion and the transfer of 
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force from one bone to another.  The tissue is connected to the subchondral bone through 
a calcified cartilage layer.  Blood vessels do not penetrate the subchondral bone; 
therefore, the chondrocytes receive nutrition via diffusion from synovial fluid.  
Unfortunately, the combination of the absence of a direct blood supply and the low 
cellularity of the tissue contributes to the limited capacity for repair of articular cartilage.  
Injuries that penetrate the subchondral bone undergo repair through the formation of 
tissues usually characterized as fibrous, fibrocartilagenous, or hyaline-like, depending 
upon the species, age of the animal, and the location and size of the injury.5-7  However, 
these reparative tissues, including those that resemble hyaline cartilage histologically, 
differ from normal hyaline cartilage both biochemically and biomechanically, and by six 
months, fibrillation, fissuring, and extensive changes occur in the reparative tissues of 
approximately half of the full-thickness defects.6,7  This often leads to secondary 
osteoarthritis resulting in pain and disability.   
Osteoarthritis (OA) affects 40,000,000 Americans, is the second most common 
cause for long term disability, and is expected to affect 18.2% of the population by 2020.1    
Eighty percent of patients diagnosed with OA report limited ability and 25% cannot 
perform major daily activities.8  Numerous surgical and medical treatments are used to 
treat OA; including autologous chondrocyte implantation, debridement arthroplasty, and 
conservative management (including weight loss, moderate exercise, and non-steroidal 
anti-inflammatory medication).  Total joint arthroplasty, is the final treatment option for 
OA that has been resistant to other therapies.   
 
Currently Available Treatments  
Treatments have been developed to prevent or delay total joint arthroplasty.  
Initial treatment options for OA include transplantation of whole joints, partial joints, 
osteochondral segments, and autologous chondrocyte implantation.9,10 The success of 
each of these techniques is limited.  Although whole or partial joint transplantation may 
be used for any size defect, it requires a healthy cadaver donor that is size matched.  
Additionally, there is risk of disease transmission and rejection of the transplanted tissue. 
Decreased cell viability at the time of transplantation is also an issue creating morbidity.10  
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Osteochondral autografts or mosaicplasty is a procedure requiring harvest of a 
cartilage and subchondral bone graft from a portion of a joint with minimal weight 
bearing and transplantation to the affected portion.  The disadvantages of this procedure 
include donor site degeneration and pain, insufficient graft to harvest, and ideally 
limitation to 1-2 cm lesions.10  Additionally, the transplanted cartilage does not integrate 
with the surrounding cartilage.11   
Autologous chondrocyte implantation requires an initial surgery to harvest 
chondrocytes by removing 200-300 mg of cartilage from a portion of the joint with 
minimal weight bearing.10  The chondrocytes are released from the matrix and 
proliferated in culture.  In a second surgery, the cells are placed into the defect under a 
periosteal flap sealed with fibrin.  At first, repair tissue forms more quickly than control 
defects; however, integration with surrounding cartilage as well as biomechanical 
stability of the tissue remains problematic.9,12  Additionally, this method has limited 
clinical application in the repair of large or multiple defects of articular cartilage because 
of the limited availability of donor material.9,10,13   
Joint resurfacing with tissue engineered materials is a relatively new paradigm.  
Although preliminary results have shown promise in animal models, full regeneration of 
the normal cartilage surface has not been accomplished. 
When the pain and debilitation of OA returns, patients are left with the choice of 
arthrodesis or arthroplasty.  Arthrodesis entails fusion of the joint eliminating motion and 
limiting function.  Total joint arthroplasty effectively replaces the articulating surfaces of 
a joint with synthetic materials designed to preserve range of motion providing a more 
favorable clinical outcome. 
 
Total Joint Arthroplasty 
Total joint arthroplasty is performed nearly 500,000 times per year in the hip 
alone, and its frequency increased 50% over 13 years as the mean age and activity of the 
general population increases in North America.14,15  Arthroplasty generally restores 
function; however, the rate of total hip arthroplasty revision surgeries is up to 30% with 
 5 
only 72% of implants surviving 10 years.16  Aseptic loosening (ASL) is the leading cause 
of surgical revision (70% of total hip revision, 44% of total knee revisions).17   
Aseptic loosening occurs because of the patient's natural remodeling response to a 
foreign material that has been surgically introduced. The foreign materials (metals, 
plastics, and ceramics) that currently represent the articular surface of all joint 
arthroplasty systems shed microscopic wear debris that cause an inflammatory response 
activating the cells that resorb bone (osteoclasts and macrophages) and suppress 
osteoblastic (bone forming) activity.  Wear debris activates macrophages through several 
mechanisms.  In turn, macrophages secrete interleukin 1 (IL1), tumor necrosis factor 
alpha (TNFα), prostaglandin E2 (PgE2), and interleukin 6 (IL6).17,18  These cytokines 
inhibit osteoblastic bone forming activity and stimulate osteoclastic differentiation and 
activity.  The overall effect is resorption of the bone-implant interface and ultimately an 
unstable implant.  
Research has improved materials leading to a reduction in wear particles, but the 
rate of ASL has not significantly decreased.  Although metal on metal or ceramic on 
ceramic implants produce less debris, metal debris can be carcinogenic, affect intellectual 
capacity, or decrease hematopoesis.17  Ceramic particles have caused cytokine release 
from macrophages in vitro.17  Zirconia ceramics may also be directly cytotoxic.17  Other 
improvements in materials include porous ingrowth surfaces or hydroxyapatite 
coatings.19  Hydroxyapatite lowers the histologic migration or wear debris, but has not 
been evaluated clinically in humans.  Other efforts have been focused on improving high 
molecular weight polyethylene (commonly used in arthroplasty).17,18  There is evidence 
to suggest that decreasing the oxidation of polyethylene will decrease the amount and 
reaction to debris.17,18 
The fields of tissue engineering research and regenerative medicine pursue a 
solution to the problem by preventing the need for total joint arthroplasty by repairing 
focal defects or replacing the implant material interface with a cartilage on cartilage 
interface.  This latter option would eradicate wear debris thereby eliminating or 
significantly reducing ASL. 
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Canine Model 
The canine model is an appropriate clinical and laboratory model for several 
reasons.  First, OA is a naturally occurring disease in the canine affecting 1 in 5 adult 
dogs, and causing disability in 62% of dogs affected.14,15 Secondly, the canine is already 
an established model for hip arthroplasty, aseptic loosening and OA.20-22  Joint 
articulation angles and range of motion are similar to humans.  Although cattle and sheep 
are also used as models for arthroplasty because of larger joints, housing, handling, and 
expense are distinct disadvantages.  The rabbit is commonly used to model cartilage 
tissue engineering due to housing and cost issues; however, the joint angles are not 
similar to humans, and articular cartilage is only <0.5 mm compared to 2.5 mm on 
average in human cartilage.21,23   Dogs have articular cartilage thickness that is greater at 
1 mm in depth.24  The main disadvantage of a quadrupedal model is that it may not 
accurately represent bipedal loading.  This is only alleviated by the use of non-mammals 
such as birds or non-human primates. 
Another advantage of using a canine animal model is that clinical outcomes can 
be assessed objectively.  Although it is often ignored, clinical outcome is as important 
and histologic or biochemical outcome when designing a treatment for OA.24  Gait 
analysis is an established and accepted method of measuring clinical outcome related to 
the orthopedic procedures in dogs.25,26    Objective clinical outcome measures of lameness 
are not commonly practiced in rabbits, cattle, or sheep.   
 
Clinical Outcome Measures 
 There are several outcomes of OA treatment that are detectable from a variety of 
methods.  However, from a patient’s perspective, the desired outcome would be 
decreased pain and increased joint function. Evaluation of pain is subjective and variable.  
A visual assessment score (VAS) is a 10 mm line that represents a continuum from no 
pain to the most pain possible.  The patient or pet owner marks on the line accordingly.  
Numerical rating scales (NRS) are similar except these scoring systems use a numerical 
score for specific aspects of pain or lameness.27,28  This becomes more complicated when 
evaluating dogs that cannot verbally communicate with people.  Instead, the owner or 
 7 
veterinarian must use behavioral cues to determine the pain of the animal.  The inherent 
variation produced with subjectivity compounded by difficulty interpreting canine 
behavior is not ideal for determining clinical outcomes. 
 Although pain cannot be truly known in animals, it is reasonable that degree of 
lameness detected would be correlated to pain.  Force platform gait analysis is a well 
established method of determining limb function in human and veterinary medicine.  
More specifically, force platform gait analysis has been used to determine improvements 
in limb function after both surgical and medical interventions.29-31   This outcome 
measure is also objective and non-invasive. 
 Although force platform gait analysis is easily performed, strict control of certain 
variables must be maintained in order to limit variation.  In general, a valid trial is 
described as one in which the dog places a forelimb on the platform followed by the 
ipsilateral hindlimb without concurrent placement of contralateral paws.  Additionally, 
velocity and acceleration are maintained within 0.3 m/s and 0.5m/s2, respectively whether 
the gait chosen is at a walk or trot.29,32,33  Five trials are collected for each dog.  The 
number of trials was determined with mathematical modeling techniques using the data 
from normal dogs by Jevins in 1993, and has become convention for studies involving 
lame dogs.29,31,33,34  Although the data used for determining the trial number is based on 
normal dogs, dogs with chronic OA have low intradog coefficients of variation.35   
 Additionally, the intraclass correlation using peak vertical force in lame dogs was 
96.5%. (Unpublished data)   This means that the intradog variation is much lower than 
the variation from dog to dog. Intraclass correlation was used to determine the estimate of 
the standard deviation.  The estimate of standard deviation was relatively unchanged 
when using 5 and 50 trials (6.22% and 6.20%, respectively).    
 Additional sources of variation include handler, dog acclimation, day to day 
variation, and subject morphology.36-38  Variation induced by different handlers can also 
be attenuated by experience.34  However, subject morphology is a significant source of 
dog to dog variation in ground reaction forces.33,39,40  To account for these differences, 
the ground reaction forces are standardized by subject weight.33,39  Comparing the change 
in ground reaction forces from pre- to post-treatment values reduces this source of 
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variation further.41  Additionally, block randomization may be used to evenly distribute 
dogs of different morphologies to treatment groups. 
 Radiographic evidence of OA and its progression is commonly used as an 
outcome measure in human and veterinary medicine.27,42-45  Plain film radiography is 
routinely performed, takes minimal time, is relatively inexpensive and non-invasive.  
Disadvantages include variation in positioning and radiograph quality, subjectivity of 
evaluation, and x-ray exposure.  Additionally, because radiographs are routinely 
performed for surgical follow-up, retrospective studies commonly use radiographic data 
for outcome.42-45 
 Radiographic data can be obtained through descriptive means or by using 
published scales to assign a number to the aspect being evaluated.43 In osteoarthritic 
joints, swelling or joint effusion, subchondral sclerosis, osteophytosis and 
enthesiophytosis are often assessed as part of the scoring system.   
Joint collapse is regarded in the human literature as an accurate measure of 
cartilage structural integrity.46 However, controversy surrounds radiographic evidence of 
joint collapse because variation in positioning commonly causes artifactual radiographic 
collapse.47  Additionally, the preferred views are not standardized, and there is high 
interobserver variation when assessing collapse.46  This is accentuated when the limb is 
not weight bearing when radiographed, as occurs most often with veterinary patients.   
 Intuitively, since radiographs are an indicator of pathology, radiographic evidence 
of OA should correlate to pain and disuse.  However, radiographic signs do not change as 
rapidly as other modes of detection (i.e. magnetic resonance imaging).36,47,49  
Nevertheless, the correlation of radiographic severity of OA to the pain and function 
remains controversial.27,35,49-51  Several authors in the veterinary literature have 
commented on the apparent disconnect between radiographic severity and subjective 
evaluation of the patient’s condition.29,36,43,45,48,50-54  Furthermore, many noted an increase 
in radiographic severity of OA while subjectively noting functional improvement.43,45,50,52  
Despite common use as an indicator of disease, the presence of osteophytes is not 
correlated with subjective evaluation of pain.27  In contrast, Evers et al. found a good 
correlation between radiographic score and limb function in the dogs with OA in the 
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hip.51  The relationship between radiographic OA and limb function has not been 
objectively evaluated using force platform gait analysis. 
 
Future Treatment: Joint Resurfacing 
 Regenerative medicine is an emerging field of research that includes the 
application of molecular and tissue engineering techniques to promote tissue repair with 
functional, and adaptable tissue instead of replacement with scar tissue.  One approach to 
regenerating the cartilage surface of a joint is by combining cells with a 3-dimensional 
matrix.  There are 3 major aspects to this approach: cell type, scaffolding, and culture 
conditions. 
 
Cell Type and Source 
 The cell type most suitable for cartilage regeneration is debatable.  The most 
commonly utilized cells for cartilage tissue engineering are chondrocytes and 
mesenchymal stem cells (MSCs) which show promise for rapid extracellular matrix 
production.9,10,13,55-87  Mesenchymal stem cells can be harvested from the umbilical cord, 
bone marrow, and adipose tissue.88  Each type of MSC has different characteristics.  
Umbilical cord MSCs are more difficult to successfully harvest than MSCs or adipose but 
they have greater capacity to proliferate prior to senescence.88   Bone marrow derived 
MSCs senesce after fewer passages than the other 2 types.88 
Mesenchymal Stem Cells can be harvested with minimal morbidity to the patient, 
and they can be easily proliferated to appropriate numbers in vitro for reimplantation.55  
However, the number of MSCs per 100,000 nucleated bone marrow cells decreases from 
1 in a newborn to 0.1-0.05 in an 80 year old human.89  Another disadvantage of MSCs is 
the time needed to proliferate and differentiate the cells.   
Chondrocytes also have a finite number of passages prior to senescence.57 
Chondrocytes can be harvested from the ribs, articular surface, auricular cartilage and 
nasal septum.90  As with the MSCs, there are differences in chondrocytes from different 
locations.  For example, auricular and nasal chondrocytes produce elastic collagen in 
addition to the more desirable collagen type II.90   However, chondrocytes harvested from 
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the nasal septum and ribs have produced more collagen type II and aggrecan than 
articular chondrocytes in direct comparisons.90  Additionally, when using articular 
chondrocytes donor site morbidity may incite inflammation and exacerbate OA, and cells 
collected from osteoarthritic joints and/or the aged may not provide the same 
potential.10,57,85 Despite the disadvantages, chondrocytes are a differentiated cell-type and 
have the potential for cartilage formation reducing the time needed to grow an implant.  
Chondrocytic potential is highlighted by the results of autologous chondrocyte 
implantation which shows short-term improvement in 62-89% of patients.10 
The immunologic potential is also a factor when considering a cell type.  
Autografts are non-immunogenic, but allografts but may be used when adequate numbers 
cannot be harvested.  Also, using allografts reduces the number of procedures required 
for the patient, and potentially decreases the time from diagnoses to surgical treatment. 
The immunoregulatory role of MSCs is a potential advantage, although this use is 
controversial and likely dependent on the microenvironment.55,91  There is in vitro 
evidence that MSCs inhibit proliferation of immune cells and cytokine excretion; 
however, they may also serve as antigen presenting cells stimulating T and B cell 
immunity.91   Inflammatory cytokines may also enhance the immunomodulatory function 
of MSCs.  In vivo, autologous MSCs help attenuate induced inflammatory reactions like 
experimental autoimmune encephalitis, but in contrast, fails to assuage collagen induced 
arthritis.91 
Although chondrocytes are not immunosuppressive, they may be less antigenic 
than other cell types.92,93  When chondrocytes were isolated from pathogen free mice, 
major histocompatibility complex (MHC) I and II were not expressed and only 
occasionally expressed in non-isolated mice.92  These proteins play a large role in 
immune recognition of foreign cells.  However, inflammatory stimulation by TNFα 
produced expression of both MHC I and II.92  Cells could also present antigens for T cell 
stimulation although not as efficiently as antigen presenting cells.92  Transplantation of 
chondrocytes in vivo has given mixed results.  Several studies in rabbits with 
chondrocyte allograft transplantation show no response or transient inflammation that 
recedes.93  Theoretically, this protection afforded allografts is due to a physical barrier to 
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immunologic surveillance by extracellular matrix or scaffold.93  Additionally, it is 
proposed that exposed allografted chondrocytes would require only temporary 
pharmacologic immunosuppression while extracellular matrix was formed.93   
 
Scaffold 
The scaffold of a tissue engineered implant is nearly as important as the cellular 
component.  In general terms, the ideal characteristics for a scaffold for osteochondral 
tissue engineering include allowing cell attachment, porous, allow diffusion of nutrients 
and bioactive molecules, allow integration with native tissue, provide appropriate cell 
signaling, and have appropriate mechanical characteristics for the site of implantation.94    
There are many scaffolds used in tissue engineering research.  These range in strength, 
texture, porosity, and biointeraction. It is well documented that the interaction between 
cells and the extracellular matrix influences proliferation, differentiation, attachment and 
migration, and the effect of growth factors.63,95,96  For example, cellular attachment via 
integrins regulates growth factor receptor activity and growth factors can be bound for 
later use in the extracellular matrix.63,97,98   
Tantalum trabecular metal is made from elemental tantalum deposition onto a 
carbon fiber skeleton.  The trabecular component refers to the multiple interconnecting 
pores which resemble cancellous or trabecular bone.  The construct also, has the 
mechanical characteristics of cancellous bone and provides structural support while bone 
ingrowth is occurring.99   Tantalum has been FDA approved as a surgical implant material 
for osteoconduction.  The bulk porosity exceeds 80% which favors boney ingrowth while 
still maintaining sufficient mechanical strength to avoid collapse.99  Tantalum trabecular 
metal has unparalleled mechanical and tissue compatible characteristics with a modulus 
of elasticity near that of cancellous bone.  The modulus of elasticity is important because 
it is a measure of stiffness of the implant.99  An implant that is too stiff creates a 
mismatch of the elastic modulus at the bone-implant interface is prone to failure.100 
Alternatively, other metal implants have a strength and stiffness that is 5-10X that of 
normal bone and to date chondroconductive polymeric implants are too weak for 
immediate load bearing.   
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Many of the polymeric-cell constructs provide excellent short-term healing 
compared to empty controls; however, long-term implants have proved inadequate, 
degrading over time.12,56,101  One hypothesis is that the scaffolds are resorbed too quickly 
leaving vulnerable neocartilage unprotected from the stressful environment.102,103     
These stresses may be compounded by insufficient polymeric strength to resist cellular 
contraction in vivo.  For instance, collagen is used commonly as a biomaterial and has 
been heavily researched as a delivery vehicle for chondrocytes.66,74  However, 
chondrocytic or MSC contraction can shrink the polymeric implant by 50%.66  In contrast, 
tantalum trabecular metal has sufficient strength to maintain its shape under physiologic 
stress.  Additionally the tidemark, or subchondral bone, does not reform leaving the 
neocartilage without foundation.102,103  Tantalum is non-resorbable and mechanically 
similar to bone conceivably increasing the probability of successful support for 
neocartilage long-term. 
 
Culture Conditions 
 The ideal culture conditions for cartilage tissue engineering vary based on cell 
type, source and species. 9,21,57    However, these conditions can be categorized into 3 
interrelated features of the total in vitro environment.  The biochemical, physical and 
mechanical aspects of the environment play large roles in the success of tissue 
generation.  Optimizing each in relation to the others is an important step in growing a 
consistent, quality product.  
The biochemical environment appears to be the most researched aspect of the 
culture conditions relating on culture nutrients and growth factors.  This is likely due to 
the complicated responses to growth factors that may fluctuate due to stage of 
differentiation, age of cells, passage number in vitro, mechanical and physical 
environment, and individual animal differences.21,57  There are many different growth 
factors with the potential to initiate or enhance chondrogenesis.60,61,68,69,82   The growth 
factors emphasized to play a role in differentiating MSCs or redifferentiating 
chondrocytes are FGF2, TGFβ, and IGF.  The effect of growth factors published in the 
recent literature are summarized in Tables 1 and 2. 
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TGFβ has been heavily studied with regards to MSC differentiation as well as a 
tool to prevent dedifferentiation in cultured chondrocytes.61,63,64,67,69,78,81,82 The value of 
TGFβ in adult chondrocytes is controversial.64,67,78 Some studies show a dose dependant 
toxicity of TGFβ on chondrocytes.67  Others show an increase in matrix production and 
maintenance of type II collagen production.64,78  Additionally, differences likely exist in 
the induction of differentiation between isotypes of the cytokine.  MSCs possess 
receptors for both TGFβ1 and TGFβ3.  There is some evidence to suggest that TGFβ1 
may predispose the newly differentiated chondrocytes to become hypertrophic leading to 
an osteoblastic lineage or apoptosis.82  In conflict, more consistent levels of TGFβ1 may 
be protective against differentiating into an osteoblastic lineage.60,63,82   
FGF has also shown the ability to differentiate MSCs into chondrocytes.80,82  
FGF2 added to the media of replicating MSCs has been shown to predispose them to a 
chondrocyte lineage once pelleted.69,80,82  Chondrocytes respond to FGF2 by increasing 
matrix production in 3 dimensional culture and proliferating in monolayer.74   In addition, 
FGF2 has been shown to increase healing in large defects in rabbit stifles.104,105  In 
theory, the mechanism includes encouraging mitogenisis and differentiation of 
endogenous MSCs at the site of injury.104,105  FGF2 has unique qualities that may benefit 
the speed or quality of extracellular matrix produced by either chondrocytes or MSCs. 
Combinations of cytokines may be the most chondrocytic.  IGF has been shown 
to enhance the effect of FGF2, TGFβ3, and TGFβ1 in MSC culture, although the actions 
of insulin-like growth factor (IGF) alone are debated in the literature. 59-61,69,77-82  
Additionally, FGF2 supplemented medium during the proliferation of MSCs in 
monolayer has improved the matrix composition of pellets differentiated by TGFβ.69  
FGF2 in monolayer may also increase the time to senescence of adult chondrocytes in 
vitro as well as enhancing matrix formation after 3-dimensional culture. 
Other major factors in the culture conditions that make a difference in response to 
growth factors include serum, dexamethazone, and ascorbic acid.  Serum is a factor that 
adds a tremendous amount of variability to cell culture.106-108  Differences between lots of 
serum are profound and require serum testing with the cells to establish an appropriate lot 
for culture maintenance.94  Serum diminishes the ability of chondrocyte production of 
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extracellular matrix formation both in vivo and in vitro.107  In monolayer, type I collagen 
expression is upregulated and collagen type II is downregulated in serum containing 
cultures.108  Additionally, serum can enhance the toxicity associated with TGFβ1.83  
Another disadvantage of serum culture conditions includes potential increased 
immunogenicity of cultures placed in vivo.  Chondrocytes cultured in fetal bovine serum 
can present the xenogenic proteins even after implantation in vivo.109   
Dexamethasone and ascorbic acid are reported as required elements of 
extracellular matrix formation in vitro.  Dexamethasone promotes redifferentiation and is 
commonly used in 3-dimensional serum-free culture.74,107 Sekiya found dexamethasone 
had a dose dependent increase in sox9 which is a transcription factor that activates 
collagen type II gene expression.110  However, Mizaki reports that dexamethasone 
inhibits the ability of TGFβ1 to upregulate collagen type II.111   Furthermore, it can also 
induce apoptosis of chondrocytes even at doses in the range used for chondrocyte 
culture.112,113   
Ascorbic acid is also commonly used in 3-dimensional culture.  Collagen and 
aggrecan are increased in chondrocyte culture with ascorbic acid; however, the cells also 
showed signs of oxidative damage.114  In monolayer, there is evidence that ascorbic acid 
increases proliferation rate and maintains phenotype.115 
The physical environment affects the actions and reactions of cells in vitro.  
Chondrocytes in monolayer dedifferentiate and proliferate.  Three-dimensional culture 
maintains differentiation and promotes matrix formation.  Not all 3-dimensional culture 
systems are equally effective.  Specific scaffolds add an additional element to 3-
dimensional culture.63,97,108  The affect of scaffolds on culture systems were discussed 
previously. 
Cell seeding of a scaffold is important for even distribution of engineered 
matrix.116  Typically initial high cell densities are required for cartilage formation in vitro 
due to vital cell to cell interactions.116   Although not fully elucidated, paracrine signaling 
is a very important mechanism for signaling matrix production.   
Oxygen tension and pH are also controlled to affect cell biosynthetic activity.  In 
normal development, low oxygen tension promotes chondrocytic cell differentiation and 
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maintenance of cartilage tissue preventing mineralization.  In vitro, both MSCs and 
chondrocytes reach senescence earlier with 21% oxygen versus 5% oxygen.117  The 
benefits of low oxygen conditions may be due to a reduction in oxidative stress.117  
Although debated, there is also evidence that matrix formation is enhanced by an acidic 
environment.  In vivo, cartilage does not have a direct blood supply which creates a low 
oxygen environment and pushes the pH toward acidity. 
The mechanical stimulation of cells supports extracellular matrix formation from 
chondrocytes and differentiation of MSCs toward a chondrocytic lineage.  Several 
different bioreactors are used to provide a dynamic stimulation in the field of cartilage 
tissue engineering including traditional stir flasks, direct perfusion, and rotating wall 
bioreactors.117-119  Dynamic environments improve cell distribution and therefore matrix 
distribution over scaffolds.106-117  As matrix increases, the diffusivity of the tissue 
decreases.118  Providing a dynamic environment facilitates increased nutrient diffusion.118   
Additionally, chondrocytes and MSCs form matrix with improved biomechanical 
characteristics when cultured in a dynamic versus static environment.119,120  More 
specifically, there is evidence that shear and compressive forces enhance the functional 
quality the neocartilage grown in vitro.106,120,121   
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Table 1.  The effect of growth factors used in monolayer culture for cartilage tissue 
engineering.  1 
 
Cell type Species
Serum 
+/- Cytokine
Dose (respective 
if >1 cytokine) Positive Indicators Negative Properties Effect on 3D
Chondrocyte
Bovine (73), 
human (84) + FGF2 5ng/ml + proliferation (84)
+ wet weight 
(73), induced 
response to 
BMP2 (73)
Chondrocyte
Caprine (62), 
rat (76), 
ovine (57), 
equine (57), 
bovine (57) + FGF2 10ng/ml + proliferation (62,57)
+ coll III mRNA (76), -
coll II mRNA (76), - 
chondrocyte 
morphology (57)
become 
hypertrophic 
(57)
Chondrocyte
Caprine (62), 
chick (79) + FGF2 100ng/ml + proliferation (62,79)
Chondrocyte Human (71) - FGF2 100ng/ml
+ proliferation (71), + 
coll II mRNA (71)
Chondrocyte Human -
FGF2, 
PDGF, EGF 
(27)
5ng/ml, 5ng/ml, 
5 ng/ml + proliferation (27)
+ coll I production 
(27)
Chondrocyte
Equine (57), 
bovine (57), 
ovine (57) +
FGF2, 
TGFβ1 10ng/ml, 5ng/ml + proliferation (57)
Chondrocyte Caprine (62) + IGF1 10ng/ml - proliferation (62)
Chondrocyte
Caprine (62), 
chick (79) + IGF1 100ng/ml
+ proliferation (62,79) + 
coll II (62) + coll I (62)
Chondrocyte
Human (70), 
canine (74) +
PDGF, 
FGF2, 
TGFβ1
10ng/ml, 5ng/ml, 
1ng/ml + proliferation (70,74)
Chondrocyte
Equine 
(60,67,83), 
Caprine (62) + TGFβ1 5ng/ml
+ proliferation (62), + 
coll II (62), +GAG (83)
- proliferation (60), + 
coll I mRNA (67), 
less GAG if serum-
free used (83)
sensitized to 
IGF (70)
Chondrocyte Caprine (62) + TGFβ1 30ng/ml
+ proliferation (62), + 
coll II (62), + GAG (83) + coll I (62)
Chondrocyte Equine (83) +/- TGFβ1 1ng/ml + GAG (83)
less GAG than 5ng/ml 
(83)
Chondrocyte Equine (83) +/- TGFβ1 10ng/ml + GAG (83)
toxic changes with 
serum (83), less GAG 
than 5ng/ml (83)
MSC
human (22), 
rabbit (22) + FGF2 unstated
+ proliferation (22), + 
time to senesence (22)
MSC Human (87) + FGF2 5ng/ml
+ immunosuppressive 
ability (87)
+ osteogenic 
differentiation (87)  
 
                                                 
1 The plus (+) and minus (-) symbols represent the presence or absence of serum or 
increasing (+) or decreasing (-) effect compared to controls. References appear in 
parenthesis.  The following abbreviations are used: Collagen (coll), glycosaminoglycan 
(GAG), proteoglycans (PG), platelet derived growth factor (PDGF), epidermal growth 
factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), 
transforming growth factor (TGF), collagen oligomatrix protein (COMP), and 3-
dimensional (3D). 
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Table 1. (continued)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell type Species
Serum 
+/- Cytokine
Dose (respective 
if >1 cytokine) Positive Indicators Negative Properties Effect on 3D( ) g y ( ) ( )
MSC
Human 
(68,69,87), 
chick (79) + FGF2 1ng/ml
+ proliferation 
(68,69,79,87) + 
sensitized to TGFβ1 
(68,69)
MSC
Human (69, 
87) + FGF2 10ng/ml
+ proliferation over other 
doses (69,84), + 
immunosuppressive 
ability (87)
+ osteogenic 
differentiation (87)
MSC Human (68) + FGF2, EGF 1ng/ml, 1ng/ml + proliferation (68)
no reaction to EGF 
alone (68)
 +sensitized 
to TGFβ1 
(68)
MSC Human (68) +
FGF2, 
PDGF 1ng/ml, 1ng/ml + proliferation (68)
no reaction to PDGF 
alone (68)
 +sensitized 
to TGFβ1 
(68)
MSC
Equine 
(60,67), 
Human (69) + TGFβ1 5ng/ml
+ coll II mRNA (67), + 
proliferation (69)
- proliferation (60), + 
coll I mRNA (67)
sensitized to 
IGF1 (60)
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Table 2.  The effect of growth factors used in 3-dimensional culture for cartilage tissue 
engineering.1 
 
Cell type Species Culture type
Serum 
+/- Cytokine
Dose (respective if 
>1 cytokine) Positive Impact Negative Impact
Chondrocytes Rabbit (64) Agarose (64) + BMP 100ug/ml
- repair in vivo (64), 
no tidemark in vivo 
(64)
Chondrocytes Bovine (73) Polyglycolic acid (73) + BMP2 10ng/ml
- no effect unless 
pretreated with FGF2 
(73)
Chondrocytes Human (73) Alginate (73) + BMP2 100ng/ml + coll II mRNA (73)
Chondrocytes Bovine (75) Alginate (75) - FGF 2.5ng/ml + coll II (75)
- mechanical 
properties (75)
Chondrocytes Rabbit (64) Agarose (64) + FGF2 5ng/ml + healing in vivo (64)
+ coll I (64), - 
tidemark in vivo (64)
Chondrocytes Canine (74) Coll II (74) - FGF2 5ng/ml
+ protein production 
(74)
Chondrocytes
Canine (74), bovine 
(75)
Coll II (74), alginate 
(75) - FGF2 25ng/ml
+ protein production 
(74), + DNA (75)
- coll II mRNA (75), - 
mechanical properties 
(75)
Chondrocytes Bovine (72) Polyglycolic acid (72) + FGF2 10ng/ml
- wet weights (72), - 
GAG (72), - FGF2 
(72)
Chondrocytes Chick (79) Pellet (79) - FGF2 100ng/ml
become hypertrophic 
(79)
Chondrocytes Canine (74) Coll II (74) - FGF2, IGF1 5ng/ml, 100ng/ml
+ protein production 
but not over FGF2 
alone (74)
Chondrocytes Equine (58) Fibrin (58) + IGF1 25ug/ml
+ coll II mRNA (58), 
+ GAG (58), + PG 
(58), +DNA (58)
Chondrocytes Bovine (75) Alginate (75) - IGF1 25ng/ml
+ coll II mRNA (75), 
+ PG (75)
Chondrocytes Equine (61) Fibrin disk (61) - IGF1 200ng/ml
+ coll II mRNA (61), 
+ PG (61),+ GAG 
(61)
Chondrocytes Bovine (75) Alginate (75) - IGF1 2.5ng/ml
+ coll II mRNA (75), 
+ PG (75)
Chondrocytes Canine (74) Coll II (74) - IGF1 100ng/ml  no effect (74)
Chondrocytes Bovine (78) Collagen (78) - TGFβ1 unstated
+ PG without serum 
(78)
- PG with >3%serum 
(78)
Chondrocytes Bovine (66) Hydrogel (66) + TGFβ1 30ng/ml
+ cell number (66), + 
GAG (66)
Chondrocytes Bovine (75) Alginate (75) - TGFβ1 25ng/ml
- crosslinks (75), - 
coll II mRNA (75), - 
PG (75)
                                                 
 
1 The plus (+) and minus (-) symbols represent the presence or absence of serum or 
increasing (+) or decreasing (-) effect compared to controls. References appear in 
parenthesis.  The following abbreviations are used: Collagen (coll), glycosaminoglycan 
(GAG), proteoglycans (PG), platelet derived growth factor (PDGF), epidermal growth 
factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), 
transforming growth factor (TGF), collagen oligomatrix protein (COMP), and 3-
dimensional (3D) 
 
 
li k (75)
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Cell type Species Culture type
Serum 
+/- Cytokine
Dose (respective if 
>1 cytokine) Positive Impact Negative Impacty ( ) g ( ) β g ( )
Chondrocytes Bovine (75) Alginate (75) - TGFβ1 2.5ng/ml
- crosslinks (75), - 
coll II mRNA (75), - 
PG (75)
Chondrocytes
Rabbit (64), human 
(65,85)
Agarose (64), 
hyaluronic acid 
nonwoven mesh (65), 
pellet (85) + TGFβ1 10ng/ml
+ healing in vivo w/ 
coll II (654,655), + 
biomechanical 
properties (655), + 
COMP (85), + GAG 
(85)
- tidemark in vivo 
(64)
Chondrocytes Bovine (72) Polyglycolic acid (72) + TGFβ1, FGF2 1ng/ml, 10ng/ml
+ wet weights (72), + 
GAG (72)
Chondrocytes Human (65)
Hyaluronic acid 
nonwoven mesh (65) +
TGFβ1, FGF2, 
PDGF
1ng/ml, 5ng/ml, 
10ng/ml - coll II (65)
MSC Human (82) pellet (82) BMP2 50ng/ml
+ coll II (82), - coll I 
(82) - COMP (82)
MSC Equine (61) Fibrin disk (61) - IGF1 200ng/ml
+ coll II mRNA (61), 
+ PG (61),+ GAG 
(61)
MSC
Human (60), rabbit 
(63)
Pellet (60), 
chitosin/collagen (63)
- (60) + 
(63) TGFβ1
Transfected active 
TGF detected was 
5ng/ml
- hypertrophic 
differentiation (60), + 
GAG (63), + dry 
weight (63)
MSC
Human (68,80), 
rabbit (80), bovine 
(86) pellet (68,80,86) - TGFβ1 10ng/ml
+ differentiation 
pretreated with FGF 
(29,80)
no differentiation 
alone (68), - coll II 
(86), + coll I (86)
MSC Human (81,82) Pellet (81,82) - TGFβ3 10ng/ml
+ coll II mRNA (81), 
+ coll II (82) + 
aggrecan mRNA (81) + coll I mRNA (81)
MSC Human (81,82) Pellet (81,82) -
TGFβ3 followed by 
IGF1 10ng/ml, 100ng/ml
+ aggrecan mRNA 
(81), + COMP (82)
no increase in coll II 
mRNA (81), + coll I 
mRNA (81)
MSC Human (82) pellet (82) - TGFβ3, BMP2 10ng/ml, 50ng/ml
+ coll II (82), - coll I 
(82), + COMP (82)  
Table 2. (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
CHAPTER 2. THE RELATIONSHIP BETWEEN LIMB FUNCTION AND 
RADIOGRAPHIC OSTEOARTHROSIS IN DOGS WITH STIFLE 
OSTEOARTHROSIS 
A paper published in Veterinary Surgery and reprinted with permission 
 
Wanda J. Gordon DVM, Michael G. Conzemius DVM, PhD, Diplomate ACVS, 
Elizabeth Riedesel DVM, Diplomate ACVR, Michael F. Besancon DVM, Richard Evans, 
PhD, Vicki Wilke DVM, and Matthew J. Ritter DVM. 
 
ABSTRACT 
Objective -To evaluate the relationship between limb function and radiographic evidence 
of stifle osteoarthrosis (OA) in dogs. 
Study Design - The relationship between force platform data and radiographic OA score 
was evaluated on 2 separate days using regression analysis. Interday variation was also 
assessed. 
Animals - Forty-one dogs with visible lameness and radiographic evidence of stifle OA. 
Methods - Force platform data was collected at a velocity of 1.7 – 2.0 m/s for 5 trials on 
day 1 and day 8.  Radiographs taken on day 1 were scored  using a previously reported 
OA scoring system.   
Results - No significant relationship was found between force platform data and OA 
score.  No significant differences were found between any day 1 and day 8 force platform 
values. 
Conclusions - Although radiographic evidence of stifle OA provides evidence of 
pathology, it does a poor job of representing limb function. In addition, the absence of 
significant differences between day 1 and day 8 values in this population of dogs supports 
use of only a single force platform evaluation before measuring a treatment effect.  
Clinical Relevance - The presence of OA in the stifle joint does not correlate with 
clinical function; radiographic outcome should be used cautiously as a predictor of 
clinical outcome. 
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INTRODUCTION 
 Several techniques are available for evaluating outcome after treatment of 
orthopedic disease.  These include subjective evaluation of pain or lameness, force 
platform gait analysis, and radiographic scoring.1-8 Lameness grade is a common rating 
system for evaluation of pain in orthopedic patients; however, this is subjective and may 
be confounded by evaluator bias.  Force platform gait analysis has been commonly used 
to compare treatment modalities and assess long-term outcome.1,2,6  It has been 
established as a reliable, objective method of quantifying lameness.  Radiographs have 
been used both clinically and experimentally as a determination of outcome.1,3,4-7  The 
presence and severity of osteoarthrosis (OA) is the primary focus of most scoring 
systems.     
Intuitively one would expect that as the severity of OA increases, the capacity for 
the patient to use the affected limb would decrease.  Empirically, however, many authors 
have suggested that there is no relationship between these two varaibles.1,10-14  Several 
clinical studies have reported that the progression of radiographic score is in contrast to 
the clinical improvement or lack of progression of clinical signs.3,7-9  Furthermore, Roy et 
al. found that lameness score did not correlate with radiographic OA score in stifles with 
medial patellar luxation.8  All of these reports, however, used subjective scoring systems 
to evaluate patient limb function.  Using force platform gait analysis as an objective 
measure of outcome may be more sensitive than a subjective lameness score. 
Our objective was to evaluate the relationship between limb function, as measured 
by force platform gait analysis, and radiographic evidence of OA in dogs with stifle 
osteoarthrosis.  We hypothesized that there would be a strong correlation between limb 
function and radiographic OA score. 
 
MATERIALS AND METHODS 
Owners of dogs with history and physical examination findings consistent with 
unilateral lameness caused by stifle OA were recruited for this study.  Criteria for 
inclusion were as follows: history and physical examination findings consistent with 
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lameness from a single joint, no administration of non-steroidal anti-inflammatory 
medications for 2 weeks or steroidal medications for 4 weeks, no surgery on the affected 
limb in the previous 6 months, and the animal patient's gait was adequate for appropriate 
force platform trial acquisition.   
 
Force Platform Measurement 
All dogs had force platform and radiographic examinations on day 1.  Force 
platform examinations were repeated on day 8.  Dogs were trotted across a force platform 
(AMTI OR-6, Watertown, MA) at a velocity between 1.70 and 2.00 m/s and an 
acceleration of ± 0.5 m/s2.  The first 5 acceptable trials of the affected leg were used to 
generate mean force platform values for velocity, acceleration, peak vertical force (PVF), 
vertical impulse (VI), breaking, and propulsion for the affected limb. Trials where one 
front limb struck the center of the plate with no other limb present followed by the 
solitary ipsilateral hind limb were considered acceptable.  All data were expressed as a 
percent of bodyweight. 
 
Radiographic Examination 
A board-certified radiologist, unaware of the limb function, scored cranial-caudal 
and lateral radiographs of the affected stifle. A modification of an OA scoring system 
reported by Vasseur,7 was slightly modified for use in this study. Eighteen separate 
categories were scored on each set of radiographs using a numeric scoring system from 0-
3 for none, mild, moderate, or severe signs of OA respectively.  The mean OA score was 
calculated from the categorical scores and used for statistical comparison. 
 
Data Analysis 
Regression analyses were used to evaluate the relationship between the mean 
radiographic OA score and the force platform values for each of the 2 examinations.  
Paired t tests were used to compare the variation between days 1 and 8 in the force 
platform data.  The level of significance for each set of statistical tests (regression: P< 
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.008, t test: P< .006) was adjusted using the Bonferroni method to decrease the chance of 
falsely concluding a relationship exists.15  As multiple tests were performed on related 
data, the chances of a type I error increase by 0.05% for each test .15 
 
RESULTS 
 Forty-one dogs that fit the inclusion criteria were studied. The affected stifles 
were evenly distributed between the left and right limbs. Seventeen were male and 24 
female, and although multiple breeds were represented, 13 dogs were Labrador 
Retrievers.  
The mean velocity (± SEM) on both day 1 and day 8 was 1.81 (± 0.01) m/s.  The 
mean acceleration on day 1 was 0.06 (± 0.03) m/s2 and day 2 was 0.03 (± 0.02) m/s2.  
Mean (± SEM) values for each of the force platform variables on both days are listed in 
Table 1. The mean radiographic OA score was 0.91 (range, 0.17 - 1.50).  No statistically 
significant relationship was found between OA score and PVF (day 1: P = .95; day 8: P = 
.81), VI (day 1: P = .01; day 8:  P = .09), breaking force (day 1: P = .16; day 8: P = .32), 
breaking impulse (day 1: P = .55; day 8: P = .09), propelling force (day 1: P = .19; day 8: 
P = .60), or propelling impulse (day 1: P = .99; day 8: P = .80).  No significant difference 
was found between any day 1 and day 8 force platform values (P > .006).  
 
DISCUSSION 
 This data strongly suggests that there is no relationship between limb function and 
the severity of radiographic signs of stifle OA.  Conventionally, the relationship between 
OA score and VI on day 1 would be considered significant; however our level of 
significance was reduced.  When multiple individual statistical tests are performed each 
at the 0.05 level of significance on related data, the chances of making an incorrect 
conclusion increase with each test by 5%.15  Consistent with this ideology, the regression 
coefficient of day 1 VI and OA score is positive, which suggests that limb function 
improves as OA increased.  This conclusion would not be logical.   
The results from this study corroborate those of previous studies.  Radiographic 
OA scores did not correlate with the force platform values in a retrospective study of 
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humeral condylar fracture repair,16 and Roy et al, 8 found that there was no correlation in 
a subjective limb use score and radiographic score for stifle OA after medial patellar 
luxation. Studies in humans correlating radiographic pathology and pain have also 
reported results consistent with our results.10,11  Cobb and others found that only 30% of 
people with radiographic signs of OA in the knee, had pain at relevant sites, and no 
association was found between radiographic OA and stiffness as perceived by the 
patient.10  Although direct correlations between radiographic OA and limb function are 
limited, various authors have published statements that compliment our results based on 
empiric observation.1,10-14   
In contrast, Evers and others published a follow-up study on coxofemoral luxation 
showing physical examination score and radiographic OA score correlated well (r=0.63).9  
This was attributed to the accuracy of the subjective scoring system. Although it is 
possible that the relationship between limb function and OA score is different for the hip 
and stifle joints, we feel that the objective nature of force platform gait analysis supports 
our conclusions.  
The population of dogs in our study all had histories and clinical signs consistent 
with OA.  By excluding normal dogs from our study population, we eliminated the 
influence that those dogs would have had on the association of radiographic score to limb 
function.  Although we cannot generalize about the entire population of dogs, we are able 
to draw conclusions relating to the smaller population of dogs with OA.   
Additionally, by using the mean OA score for the 18 individual locations for 
radiographic changes, continuous, more precise data was generated when compared to 
scoring a radiograph based on an overall impression.  When an overall impression is used 
to classify a radiograph (eg, mild, moderate, severe) a range of severities are present 
within each classification.  For example, within the radiographs scored as moderate, there 
are those that almost qualify for the severe classification and those that are barely more 
severe than mild.  The advantage of using the mean score of several anatomic categories 
is that the continuous data allows for a more specific OA score. This combined with 
scoring all radiographs at one time by a board-certified radiologist we feel produced a 
more accurate score for each radiograph.  However, the scoring system may still be 
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improved by weighting certain categorical locations associated with increased pain over 
others. Unfortunately, since pain is difficult to pinpoint and quantify in veterinary 
patients, data used to weight the categories would need to be extrapolated from human 
studies.  To investigate this, multivariate regression was performed on the individual 
categories for day 1 to assess the effect of the individual category on the PVF or VI, but 
similar to the overall score, none were significantly related. 
As imaging modalities continue to improve and become more common, it is 
possible that quantification of pathologic changes will correlate better with clinical signs.  
Nuclear scintigraphy has shown a positive association with clinical signs and may be a 
more sensitive indicator of the loss of function associated with pain and inflammation.17 
Increased detail and 3 dimensional imaging may improve the sensitivity of the evaluation 
to small changes.  Magnetic resonance imaging can detect OA up to 4 weeks earlier than 
radiographs.14 Soft tissue changes are also more readily identified by this method, and 
pain is often caused by changes in the periarticular tissues.11 However, because pain 
remains an individual experience, disparities in degree of lameness when compared to a 
range of lesions will continue to be unpredictable.   
Although significant variation in data collected between days has been reported,18 
we found no significant differences between day 1 and 8 values in this population of 
dogs.  In the previous report, dogs with interday variation were evaluated using the force 
platform on 3 consecutive days.18 The dogs may have become habituated to the routine, 
or although they were normal on orthopedic exam, trotting may have caused discomfort, 
which affected the gait analysis on subsequent days.11,19 In our study, the 7 day period 
between gait analyses may have precluded the same level of adaptation and given dogs 
ample time to recover from overuse. Other sources of variation found in normal dogs 
using force platform gait analysis include subject morphology and handler.20,21  In our 
study, more than one handler was used, but all handlers were experienced, and although 
morphology may play a role in variation, using the same dogs on both days eliminated 
this as a source of error.   
Although the presence of stifle OA provides evidence of pathology, it does a poor 
job of representing animal patient limb function. Studies evaluating the patient's 
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prognosis after treatment of a condition of the stifle in the dog should not focus 
exclusively on radiographic outcome.  Additionally, we found no difference in limb 
function between day 1 and day 8 of the dogs in this study providing evidence that only a 
single force platform evaluation before measuring a treatment effect is necessary.  
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Table 1. Mean and Standard Error of the Mean Values for Force Platform Variables 
Presented as a Percent of Bodyweight. 
 
Day 1 Day 8 
Force Platform Variable Mean % SEM % Mean % SEM %
Peak Vertical Force 51.10 1.78 51.38 1.72 
Vertical Impulse 8.31 0.31 8.34 0.29 
Breaking Force 4.75 0.35 4.82 0.30 
Braking Impulse 0.43 0.15 0.29 0.03 
Propelling Force -6.04 0.31 -6.22 0.29 
Propelling Impulse -0.75 0.17 -0.60 0.03 
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CHAPTER 3.  THE CHONDROCONDUCTIVE POTENTIAL OF TANTALUM 
TRABECULAR METAL  
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O’Driscoll4 
 
ABSTRACT 
Mesenchymal stem cells or chondrocytes have been implanted into joints in 
biodegradable matrices in order to improve the quality of healing cartilage defects; 
however, insufficient biomechanical strength of the construct at implantation is a limiting 
factor for clinical application. Logically, a construct with better biomechanical 
characteristics would provide better results.  Tantalum trabecular metal (TTM) is 
osteoconductive and mechanically similar to subchondral bone.  The objective of this 
pilot study was to determine if TTM is also chondroconductive.  Small sections of TTM 
were cultured with emu and canine chondrocytes in static and dynamic culture 
environments.  The sections cultured in dynamic bioreactors were diffusely covered with 
a cartilaginous matrix. Sections cultured in static conditions had no growth.  Histologic 
evaluation from emu and canine dynamic cultures showed tissue that was heavily 
populated with mesenchymal cells that resembled chondrocytes, and glycosaminoglycan 
staining that was distributed throughout the matrix. Type II collagen content in the canine 
dynamic culture was 84% by SDS-PAGE.  Tantalum trabecular metal is 
chondroconductive in vitro in a dynamic environment when cultured with adult canine or 
emu chondrocytes. This technology could be expanded to determine if cartilaginous-
metallic constructs may be used for joint resurfacing of osteoarthritic joints.   
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INTRODUCTION 
 It is well known that articular cartilage has a limited capacity for repair.  Injuries 
to articular cartilage that do not penetrate the subchondral bone generally do not heal and 
progress to degeneration of the articular surface.1-3 Injuries that do penetrate the 
subchondral bone undergo repair through the formation of tissues usually characterized 
as fibrous, fibrocartilagenous, or hyaline-like cartilage, depending upon the species, age 
of the animal, and the location and size of the injury.4-8  However, these reparative tissues, 
including those that resemble hyaline cartilage histologically, differ from normal hyaline 
cartilage both biochemically and biomechanically.  By 6 months, extensive fibrillation 
and fissuring occur.9-11  Once articular cartilage is damaged and osteoarthritis (OA) 
becomes clinically severe, surgical reconstruction is necessary to restore function.  
Historically, osteotomy or transplantation of whole joints, partial joints, osteochondral 
segments and cartilage-shells have been used.12-16 The success of each of these 
techniques, however, is limited by a frequent end result of progressive OA that requires 
salvage surgery such as arthrodesis or joint replacement.12-14,16 Recently, more refined 
resurfacing techniques using isolated chondrocytes, mesenchymal stem cells, and 
periosteal membranes have been investigated experimentally and clinically.10,17-22 
Mesenchymal stem cells or chondrocytes have often been implanted in joints in a 
biodegradable matrix.10,23-26  Unfortunately, these methods have limited clinical 
application for the repair of large or multiple articular defects because of restricted 
availability of donor material when autografting chondrocytes and decreased 
biomechanical strength of the construct at implantation.10,19,26    Logically, a construct 
with better biomechanical characteristics would provide better results.   
Tantalum trabecular metal (TTM) (Hedrocel® Implex Corp., Allendale, NJ) is an 
open-pore biomaterial with a bulk porosity exceeding 80% and a mean pore size ranging 
from 547 – 710 μm.27,28 Chemical vapor deposition/ infiltration creates a 1 – 5 μm grain 
size and a distinct surface microtexture.28  The implant is U.S. Food and Drug 
Administration (FDA) approved for its osteoconductive properties, has the appearance 
and mechanical characteristics of subchondral bone and provides structural support while 
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bone ingrowth is occurring.27,28  Finally, its ductility is far superior to many alternative 
naturally occurring materials or ceramics.27   
The term chondroconductive has not been used in the literature to the authors’ 
knowledge.  The definition of osteoconductive is to provide a scaffold for the ingrowth of 
bone.29-32  Using osteoconductive as a guide, chondroconductive should be defined as 
providing a scaffold for the growth of cartilage and supporting structures.     
We hypothesized that cartilage could be grown directly on TTM because of its 
high porosity and similar mechanical characteristics to subchondral bone.  The purpose of 
this pilot study was to determine the in vitro chondroconductive properties of TTM. If 
successful, this technology could lead to further investigation into new resurfacing and 
arthroplasty techniques.   
 
MATERIALS AND METHODS 
Articular cartilage was aseptically harvested from the humeral head of 4 adult 
dogs and from the knee of 1 adult emu undergoing terminal surgeries for other research.  
Species were chosen based on availability and potential for modeling human disease.  
Both species were treated separately using the same experimental protocol. 
Cartilage was finely chopped and digested overnight at 37°C in a mixture of 
collagenase type II (Sigma, St Louis, MO) and Hank’s solution.  Chondrocytes were 
washed with Roswell Park Memorial Institute 1640 with L-glutamine (RPMI) (Sigma), 
plated, and expanded for 3 weeks in monolayer culture to obtain sufficient number of 
cells for three dimensional cultures.  Chondrocyte medium containing RPMI, 10% fetal 
calf serum, penicillin (100IU/ml), and streptomycin (100μg/ml) (Sigma) was changed 
three times per week.  The canine cells from the 4 dogs were pooled for the static and 
dynamic cultures. 
Sixteen segments of TTM, 5 mm3, were cut from a commercially available TTM 
acetabular component, sterilized, and placed into a 24-well culture plate (static, canine 
n=4; emu n=4) or a magnetic stir bioreactor (dynamic, canine n=4; emu n=4). Static 
cultures were prepared by suspending aliquots of 1 X107 cells in 0.5 ml of medium which 
was placed in 4 separate wells of a 24 well plate.  A section of TTM was added to each 
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well followed by 0.5 ml of a solution of Dulbecco’s phosphate buffered saline solution 
(Sigma) and double strength RPMI containing equal proportions 20% fetal bovine serum, 
and 2% low-melting agarose (Sigma).23  The static cultures were then covered with 
chondrocyte medium plus ascorbic acid. 
Dynamic cultures were performed in a bioreactor consisting of a 300 ml magnetic 
spinner flask modified with 3 inch, 18 gauge needles to suspend the TTM pieces.  In the 
bioreactor, implants were individually fixed in place on the needles, and then immersed 
in a solution combining 1x107 chondrocytes and chondrocyte medium plus ascorbic acid. 
The bioreactor rotated at 50 rpm.  Medium was changed every other day in the static and 
magnetic stir bioreactor environments.  All cultures were incubated at 37ºC with 7% 
carbon dioxide.  
Implants were maintained in their culture environments until a tissue film was 
visibly covering the metal or after 4 weeks of culture.  For canine samples, one sample 
from each environment was placed into a vial and frozen (-20ºC) for collagen typing; the 
remaining 3 samples were fixed in 10% buffered formalin for histologic analysis.  The 
percentage of Type II collagen in the matrix was determined in the frozen tissue using a 
previously reported SDS-PAGE technique.19 Briefly, the engineered tissue was digested 
with cyanogen bromide prior to electrophoresis.  Bands corresponding to degradation 
products were stained with Phast-blue and quantified with a laser densitometer.  The 
percent of Type II collagen was then calculated.  All emu samples were fixed in formalin.  
Quantification of Type II collagen in the emu tissue-implant construct was not 
determined due to the differences in distribution of collagen type reported in birds.33  The 
constructs were embedded in glycol methacrylate, and 50 μm sections were prepared 
using the EXAKT system (Skeletech, Bothwell, WA).  Safranin-O staining was used to 
determine the presence and distribution of glycosaminoglycan.  Toluidine blue staining 
technique was used to detect proteoglycan and cellular distribution.   
 
RESULTS 
Tissue growth into and onto the TTM was histologically equivalent for both the 
canine and emu chondrocytes.  After 4 weeks, no tissue growth was present on or in the 
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TTM cultured in static conditions.  However, each implant cultured in the magnetic stir 
bioreactor had a white, translucent tissue present on its exterior. (Figure 1)  Tissue from 
the samples cultured in a static environment showed no evidence of matrix development. 
In contrast, histologic samples from the rotating bioreactor were heavily populated with 
cells that resembled chondrocytes with glycosaminoglycan staining throughout the 
matrix. (Figure 2, 3)  Finally, agarose harvested from the TTM cultured in static 
conditions contained no detectable collagen by SDS-PAGE.  Alternatively, surface 
matrix harvested from the TTM cultured in the bioreactor contained 84% Type II 
collagen.  (Figure 4) 
 
DISCUSSION 
Our findings indicate that TTM is chondroconductive in the dynamic conditions 
presented in this study.  The tissue grown on the tantalum trabecular metal constructs 
after a period of 4 weeks resembles hyaline-type cartilage in cellularity and in the content 
and distribution of matrix.  In addition, the 84% Type II collagen we found in the tissue 
grown in this study approaches that of normal cartilage.34,35 However, additional 
biochemical testing including collagen quantification, glycosaminoglycan concentration, 
and proteoglycan concentration was not performed.   
We elected to test the chondroconductive properties of TTM because its 
mechanical properties resemble that of subchondral bone, it is commercially available, 
currently used for its osteoconductive properties and it can be manufactured in many 
different shapes and sizes.  In addition, the implant is biologically inert, and it has an 
open pore structure that seemed inviting for the cartilage growth.  Similar materials may 
behave in a like manner.  Biodegradable polymers have demonstrated chondroconductive 
properties, but to the best of our knowledge none have both the structural properties for 
cartilage ingrowth and the mechanical characteristics for immediate postoperative weight 
bearing.10,23,25, 26   Polylactic acid, poly(glycolic acid), poly(L-lactic acid), collagen based 
sponges, and hyaluronan-based scaffolds have all demonstrated to be useful materials for 
cellular delivery with varying degrees of successful hyaline-like cartilage tissue 
production.10,23,25,26,36,37  
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Although TTM has many beneficial qualities that favor chondroconduction, we 
cannot comment on the reaction of engineered collagen-TTM constructs in vivo.  Shear 
forces at the collagen - TTM interface may prevent clinical improvement or even become 
detrimental. 
Recent evidence has shown that chondrogenesis is superior when the culture 
environment utilizes three-dimensional matrices or is dynamic in nature. 23,38,39   Our 
findings are consistent with these reports, where no cartilage formed in a static culture 
environment and tissue resembling normal hyaline cartilage formed in a dynamic 
environment.  Utilization of a magnetic spinner flask to create a dynamic environment is 
simple in concept, inexpensive and provides the apparent benefits of dynamic culture.  
Both hydrodynamic laminar flow (rotating bioreactor) and cyclic hydrostatic pressure 
environments improve the overall growth and maintenance of collagen producing 
chondrocytes in vitro.23,38,39 While not used in this study, intermittent positive pressure 
may also improve biomechanical strength of the growing tissue in response to the force 
applied.38  
Mechanical testing would have provided complimentary information regarding 
the ability of the construct grown in vitro to behave like hyaline cartilage in vivo.  The 
biomechanical performance of hyaline cartilage sets it apart from inferior repair tissue or 
fibrocartilage.  Since biomechanical characteristics are dependent on molecular structure, 
it is promising that the majority of collagen in our study is Type II.40  However, collagen 
type is not the only factor in biomechanical stability.  Fibril orientation also plays a role 
during compression tests in normal cartilage.40  In fact, all of the matrix components 
including the glycosaminoglycans and their organization are important in this regard.  
Engineered cartilage is typically tested in vivo by implantation instead of by direct 
mechanical means ex vivo.5,10,12,16-18,25,26   Such testing will ultimately be necessary to 
validate the concepts derived from the present study. 
Emu and canine cells were chosen based on availability and the potential for 
modeling human disease.  Articular disease is commonly studied in the canine.6,23  More 
recently, emus have been used to model avascular necrosis of the femoral head which 
leads to articular collapse.41 
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Our findings, though preliminary, indicate that TTM is chondroconductive in 
dynamic conditions.  Due to the favorable biomechanical and osteoconductive 
characteristics of TTM, further investigation is warranted to determine the suitability of 
the integration of TTM into joint resurfacing technology. 
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Figure 1. Picture of gross appearance of tantalum trabecular metal-emu cartilage 
construct. 
 
 
 
 
 
 
Figure 2.  A) Safranin-O staining of emu construct determined that glycosaminoglycan 
(GAG) was present throughout the intercellular matrix. (500x) White bar equals 200μm. 
B) Normal emu cartilage (500X) 
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Figure 3.  Toluidine blue staining of emu construct from the dynamic condition showing 
distribution of cells and extracellular matrix dark purple on the TTM (black) (200X) 
White bar equals 50μm.  
 
 
 
 
 
 
Figure 4. Results from semi-automated SDS-PAGE of the canine tissue grown 
demonstrating that 85% of the collagen present was Type-II collagen.  Bands A and B are 
used to determine the ratio of Type II collagen. 
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ABSTRACT 
Defining the ideal culture requirements for production of consistent high quality 
tissue is important for developing a commercially available implant.  This study 
investigates the use of fibroblast growth factor 2 (FGF2) in monolayer followed by 
transforming growth factor β1 (TGFβ1) in 3-dimensional pellet culture of canine 
chondrocytes.  Cells in monolayer were divided into 2 groups. One group received FGF2.  
Following proliferation, each monolayer group was pelleted using serum free medium 
with TGFβ1, FGF2, serum, or no growth factors.  Both monolayer groups receiving 
TGFβ1 in 3-dimensions were grossly larger than the other groups.  The group receiving 
TGFβ1 subsequent to FGF2 stained less intensely for glycosaminoglycans, and 
chondrocytes were less mature than the group without FGF2 pretreatment.  Additionally, 
the group receiving TGFβ1 without pretreatment with FGF2 showed more consistent 
collagen deposition; however, type I collagen was predominant.  Under the culture 
conditions presented, FGF2 is mitogenic but not chondrogenic.  In addition, TGFβ1 
stimulation produced a predominance of type I collagen. 
 
INTRODUCTION 
 Osteoarthritis (OA) is the second leading cause of disability in the United States, 
and it has been estimated that the disease will affect 18.2% of the population in the 
United States by 2020.1  Eighty percent of those diagnosed with OA have limited 
mobility and 25% cannot perform major daily activities.2 Recent efforts to improve the 
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quality of life of those afflicted have focused on joint resurfacing technologies including 
tissue engineered constructs.3-5   
  Growth factors are used commonly in an effort to improve the amount and 
quality of engineered tissue.  However, many growth factors may produce dramatically 
different results.  More specifically, Transfoming Growth Factor β1 (TGFβ1) and 
Fibroblastic Growth Factor 2 (FGF2) have produced variable results depending on the 
culture conditions, species and type of cell used.6-17  Additionally, the biosynthetic 
activity may be influenced by sequential or concomitant use of growth factors.15   
 FGF2 has been reported to be mitogenic, decrease dedifferentiation of 
chondrocytes in monolayer, increase the time to senescence, and prime the cells for 
collagen production in 3-dimensional culture.18-21  In contrast, FGF2 can also decrease 
the production of type II collagen, increase type I collagen production, and decrease the 
time to hypertrophic differentiation.8,13,22,23 
 The effect of TGFβ1 is also controversial and dependent on culture conditions.24  
TGFβ1 has demonstrated a negative effect on proteoglycan production when added to 
medium containing serum with conflicting results when serum-free medium is used.25,26  
Additionally,  TGFβ1 may increase or decrease type II collagen deposition affecting the 
biomechanical properties of the engineered cartilage.8,9,22,24 The species, cell density, and 
dose ranges present in the literature likely contribute to the variation in results.24    
Determination of the ideal culture environment for promoting the appropriate 
extracellular matrix production is important for subsequent in vivo joint resurfacing 
studies using the canine model.  Production on a clinical scale requires predictable, 
repeatable matrix grown in a relatively short period of time. 
The purpose of this study was to determine the effect of FGF2 as a pretreatment 
in monolayer on chondrocytes as well as the effect of TGF β1 on 3-dimensional pellets in 
culture.  The hypothesis was that the chondrocytes pretreated the FGF2 and cultured 3 
dimensionally with TGF β1, would have the fastest growth with the largest amount and 
highest quality of matrix produced. 
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MATERIALS AND METHODS 
Cytokines were purchased from R&D Systems, Minneapolis, MN.   All other 
components were purchased from Sigma-Aldrich, St. Lois, MO unless otherwise stated. 
 
Chondrocyte Harvest and Proliferation 
 Articular cartilage was taken from the humeral head and the femoral condyle of a 
small mixed breed adult dog estimated to be between 1 and 3 years of age that was 
euthanized for reasons unrelated to this study.  Harvested cartilage was immediately 
placed in DMEM with 1% penicillin/streptomycin.  The cartilage was diced into 1-2mm 
pieces and placed into type II collagenase in DMEM (0.5mg/ml concentration).  The 
pieces were incubated at 37ºC and 5% CO2 for 24 hours.  The released cells were 
pelleted, washed with DMEM, and counted.  Cells were plated at 0.8 x 105 cells per 
25cm2 culture flask.  Culture medium used consisted of DMEM, 10% FBS, 1% 
penicillin/streptomycin.  After the first passage, the pellets were replated in 75cm2 flasks 
with 300,000 cells and randomized to receive FGF2 at 5ng/ml or no additional cytokines.  
Media was changed 3 times per week.  When cells reached about 90% confluent, they 
were trypsinized washed and replated within the consistent group. 
 
Pellet Cultures 
 Passage 3 chondrocytes were used in 3-dimensional pellet culture.  The cells were 
trypsinized and counted.  Cells were diluted to 1 x 106 cells/ ml of serum free medium.  
Each 15ml tube was aliquoted 0.5ml of the cell solution.  The tubes were centrifuged at 
500g for 5 minutes and incubated at 37ºC and 5% CO2.  The serum free medium 
consisted of DMEM with final concentration of 0.1mM ascorbic acid, 1.25mg/ml BSA, 
10-7 M dexamethazone, 1% penicillin/ streptomycin, and 1ml/ml ITS+1 premix (10mg/ml 
insulin, 5.5 mg/L transferrin, and 5 μg/ml selenium).   
 After 2 days in 3-dimensional culture, cytokines were added to the pellets in the 
appropriate group with 10 pellets per group.  Four groups were created for each of the 
monolayer groups for a total of 8 groups:  1. FGF2 at 5ng/ml, 2.  TGF β1 at 10ng/ml, 3.  
 54 
No growth factors  4.  10% FBS.  Appropriate medium and growth factor was changed 
every 3 days for 3 weeks. 
 
Histopathology 
 Three of the 10 pellets from each group were processed for histopathology.  The 
pellets were preserved in 10% formalin for 24 hours.  To facilitate handling, the pellets 
were grossly stained with 50% hematoxylin, and imbedded in agar base.  Agar was 
heated to 38-40ºC and was pored over the pellet.  The agar-pellet construct was 
refrigerated for 10 minutes at which time the agar was solid and it was returned to 
formalin for processing. 
 The agar-pellet construct was routinely embedded with paraffin and 5 micron 
slices were prepared.   The slides were evaluated qualitatively using hematoxylin and 
eosin stains for cell morphology and safranin O with fast green counterstain for 
glycosaminoglycan (GAG) visualization.   
 In addition to subjective evaluation, the slides were also evaluated using imaging 
software to determine the percent of tissue stained by Safranin O and the density of 
viable cells.  The cell density was determined by hand marking the cells with clearly 
defined nuclei and cell borders.  Those cells with undefined nuclei and/or marked 
vacuolization were considered degenerate.  The number of cells is then expressed as a 
ratio to the area of the tissue. 
 The quantitative analysis was performed using image analysis software (IPLab 
from Scanalytics, Inc).  The area of GAG staining was quantified and expressed as a 
percent of the total area.  The number of viable cells were counted and presented as a 
ratio to the area of the H and E slides. 
 
Capillary Electrophoresis 
The remaining pellets were digested in cyanogen bromide (CNBr) and collagen 
types I and II were quantitated by capillary electrophoresis using methods  similar to 
those previously described.27-28  Pellets were preserved in RNAlater (Ambion) and frozen 
at -20◦C until digestion.   
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At the time of digestion, the pellets were thawed and soaked in PBS overnight at 
4◦C to leach out the preservative.  The pellets were then heated in 70% formic acid at 
60◦C for 1 hour followed by digestion with 5% CNBr for 48 hours.  Samples were diluted 
with distilled water to halt the reaction, and freeze dried.  The samples were then 
rehydrated in 1 mL 1% (v/v) acetic acid and heated in a water bath for 60 minutes at 
60◦C.   Samples were then filtered through MacroSpin SEC G-10 columns (The Nest 
Group, Inc.).  After filtration the sample was transferred to a 2 mL CE vial.   1 μl 
bradykinin (Sigma) at 1mg/mL and 999 μl distilled water were added to the sample vial.  
Bradykinin was used as an internal control with a final concentration of 0.5 μg/ml.   
Samples were injected (20 seconds at 1 psi, 177 nl) into a Beckman Coulter 
P/ACE MDQ Capillary Electrophoresis System coupled to a selectable wavelength 
UV/VIS detector set at 214 nm. A neutral, coated capillary (MicroSolvTech 04675-ZF) 
was used with a capillary temperature of 20◦C and sample storage at 4◦C.  The capillary 
was washed with buffer prior to sample injection. Separation was carried out at 25kv for 
60 minutes with normal polarity.  The buffer used was 100mM Sodium Phosphate at pH 
6.0.  Type I and II collagen were quantitated using a standard curve.  The standard curve 
was derived using purified type I and type II bovine collagen (Chondrex).  The R2 value 
for the type I and II collagen curves was 0.95 with a mean square error of 0.009 and 
0.0001, respectively.  Although the minimum detection limit was not sought, the lowest 
known amount of collagen used for the standard curve was 0.89 ng. 
 
RESULTS 
 The cells receiving FGF2 in monolayer took an average 3 days after passage to 
grow to confluency whereas it took 6 days until the serum only group was confluent.  
Therefore the cells that were supplemented with FGF2 in monolayer (32 days) allowed 
completion of the experiment 14 days prior to the group that did not receive the cytokine 
during monolayer culture (46 days). 
 In pellet culture, TGFβ1 had a grossly visible effect on both the pellets in both 
monolayer groups.  (Figure 1) This also was apparent in wet weight.  The pellets in both 
monolayer groups that received FGF2, serum, or no cytokines in pellet culture weighed 
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less than 0.1mg.  The group that received serum only in monolayer, but TGFβ1 in pellet 
culture had a mean weight (± SE) of 2.7mg (± 0.05). Similarly, the group that received 
FGF2 in monolayer and TGFβ1 in pellet culture had a mean weight of 2.5mg (± 0.16). 
 
Histopathology 
 Histopathologic evaluation revealed large differences between groups.  (Figures 2 
and 3) H and E stained sections showed mature chondrocytes in lacunae sparsely 
distributed across a dense matrix in the pellets treated with TGFβ1 without FGF2 
pretreatment.  This group was the most similar to articular cartilage.  The FGF2 
pretreated pellets that were also treated with TGFβ1 showed healthy mature cells in a 
matrix, but lacunae were not well formed and cells were subjectively denser than the 
group without treatment in monolayer.  (Figure 2) Image analysis confirmed this 
observation as the FGF2 pretreated group had a cell density of 1084 cells/mm2 compared 
to 495 cells/mm2 for the group that did not receive FGF2. The remaining groups did not 
show the matrix formation or the cellular maturity of the TGFβ1 treated pellets. 
The group treated with FGF2 in both monolayer and 3-dimensional culture 
showed dense cellularity with marked necrocellular debris, degenerate cells evidenced by 
pyknotic nuclei, and little to no matrix present.  The group provided FGF2 in 3 
dimensional culture, but not in monolayer showed immature cells on the periphery with 
necrocellular debris centrally.  Immature cells were defined by multiple nucleoli, 
dispersed chromatin and large nuclei.  There was not a large difference in viable cell 
population between the groups receiving FGF2 in 3-dimensional culture (3715 cells/mm2 
pretreated and 3070 cells/mm2 no pretreatment); however this group contained the 
highest number of cells by a factor of 3 over the other groups. 
The pellets cultured 3-dimensionally in serum-free media without growth factors 
showed marked necrosis centrally with a ring of immature cells in the periphery.  The 
group receiving FGF2 in monolayer but no growth factor in 3-dimensional culture 
showed cells with slightly less basophilic staining.  The groups receiving serum 
supplementation while in 3-dimensional culture, showed less debris; however, signs of 
cell death were prominent.  Irregular nuclear and cellular margins and the presence of 
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large vacuoles were considered signs of cell death.  The peripheral cells appeared 
healthy, but immature.  Basophilic matrix was more prominent in the group receiving 
serum in 3-dimensional culture without FGF2 pretreatment than the serum-free group.  
For both the serum and serum-free groups that were pretreated with FGF2 in monolayer 
(683 and 1176 cells/mm2, respectively), there were more viable cells in the pretreated 
group than the non- pretreated group (451 and 207 cells/mm2, respectively). 
Safranin O staining of proteoglycans in the matrix was present in only 3 groups.  
(Figure 3) The TGFβ1 group without FGF2 pretreatment showed uniform, intense orange 
staining and 100% of the total tissue area stained with the safranin O.  In contrast, the 
pretreated TGFβ1 group showed more diffuse, mottled staining of the extracellular matrix 
with only 51.8% of the tissue area showing staining for GAG.  The pellet treated with 
serum without FGF2 pretreatment showed a small thin ring of safranin O staining (3.0% 
of the total area) in the periphery corresponding to matrix seen on H and E stained 
sections. 
 
Capillary Electrophoresis 
Capillary electrophoresis showed type I collagen present consistently in the group 
receiving TGFβ1 without FGF2 pretreatment (mean 3.57 ug; range 1.02 – 6.00 ug).  
Additionally, this group also had one pellet with detectable type II collagen (4.5 ug).  The 
group pretreated with FGF2 followed by TGFβ1 had detectible type I collagen in only 2 
pellets 2.33 and 4.37ug.  No other group had any detectable type I or type II collagen.   
 
DISCUSSION 
 As expected, the overall size of the pellets treated with TGFβ1were grossly larger 
than the other groups, and pretreatment with FGF2 prior to 3-dimensional culture 
decreased the time to produce the cartilage.  This is a desirable effect for clinical scale 
production of engineered cartilage.  However, the groups pretreated with FGF2 had 
decreased quality and quantity of matrix histologically.  This was evident in the pellets 
treated with serum in addition to those treated with TGFβ1.   
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The larger cell number likely contributed to the size of the TGFβ1 group 
pretreated with FGF2.  This is supported by the 2-fold higher cell count/unit area 
compared to the TGFβ1 group without FGF2 pretreatment.  Consistently, the 
extracellular matrix was less prominent and stained less intensely for glycosaminoglycans 
compared to the non-pretreated TGFβ1 group despite overall equivalent size and weight.  
Although this is in contrast to some reports,19-21 FGF2 has been reported to decrease large 
proteoglycan deposition and collagen II production in 3-dimensional culture.13,22,29   
This is also apparent in the FGF2 pretreated groups treated with serum or no 
growth factors in 3-dimensional culture; whereas, the group receiving FGF2 only in 
pellet culture did not have a large difference in cell count/unit area in the pretreated 
verses non-treated monolayer culture.  Additionally, both groups treated with FGF2 in 3-
dimensional cultures had a 3-15 fold higher cell count/ unit area than the other groups.   
The higher cell numbers in the FGF2 treated groups may be due to inhibited 
apoptosis, increased proliferation, or a combination.  A similar study found that DNA 
content decreased over time in pellet culture suggesting cell apoptosis.30    This supports 
the supposition that FGF pretreatment inhibits apoptosis instead of promoting 
proliferation in the pellet cultures.  However, the cells were less mature which is 
consistent with proliferating chondrocytes.  Increased proliferation rates are consistent 
with previous in vitro studies of chondrocytes in monolayer and 3-dimensional 
studies.13,29-31  Ideally, whole pellet cell counts, DNA quantification, or proliferation 
assays would be needed to confirm this deduction.   
Unexpectedly, FGF2 pretreatment in monolayer showed lower matrix production 
when redifferentiation was induced by TGFβ1.  This is consistent with studies in 3-
dimensional cultures which show negative effects of FGF2 on GAG and collagen type II 
production when used alone.13,22 However, other studies found using FGF2 in monolayer 
enhanced the activity of TGFβ.20,30  It is possible that matrix formation may have 
surpassed the group without FGF2 treatment in monolayer if cell cultures were 
maintained for a longer period of time.  Additionally, the combination of more than 1 
growth factor may enhance the redifferentiation and matrix formation of the 
chondrocytes over individual growth factors.30,31   
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Other studies may have shown enhanced results by using a matrix instead of 
pellet culture.15,21  The presence of a 3-dimensional matrix has a significant impact on the 
effect of the growth factor.33,34  One limitation of this study is that it cannot be directly 
applied to in vitro engineering on a scaffold.   
Fibroblastic growth factor 2 also negatively influenced collagen deposition.  Only 
2 pellets out of 6 showed any collagen using capillary electrophoresis; whereas, TGFβ1 
without FGF2 pretreatment consistently produced detectable amounts of collagen type I.  
There may also be a dose dependent negative effect of FGF2 at doses of 5ng/ml or 
greater.15  In this study, 5ng/ml of FGF2 was chosen to based on a previous report 
addressing the amount optimal for mitogenic activity.15  Potentially, a lower dose would 
preserve the mitogenic activity without negatively effecting 3-dimensional culture.   
Unfortunately, only one pellet in the TGFβ1 group produced detectable type II 
collagen.  This was in the group without pretreatment.  Typically, TGFβ1 is thought to 
increase type II and decrease type I collagen production.8,9,35  However, fibrocartilage, 
the main reparative tissue of cartilage injury in vivo is predominantly type I collagne 
despite increases in TGFβ1 with injury in vivo.24  A study of the phenotypic maintenance 
of chondrocytes over time found that at 10ng/ml of TGFβ1, type II collagen was 
upregulated initially but then suppressed after 12 days of treatment.36  Additionally, 
TGFβ1 has also shown decreased levels of collagen type II mRNA in bovine 
chondrocytes exposed to 25 ng/ml of TGFβ1.22,36  One study using dedifferentiated 
chondrocytes showed TGFβ1 did not increase type II collagen unless combined with 
insulin-like growth factor 1, but production of type I collagen was consistent.32  
Combining growth factors or establishing the optimal concentration of TGFβ1 to use may 
improve the consistency and quality of the engineered tissue. 
Other aspects of the medium may also contribute to the resulting tissue 
characterization.  Despite wide use of dexamethasone in similar studies, there is evidence 
that it inhibits the upregulation of collagen type II caused by TGFβ use in vitro.24  In this 
study, dexamethasone was used in the serum-free media and may have contributed to the 
low to absent type II collagen deposition noted.  However, the overall size of the pellets 
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were grossly larger than those not receiving TGFβ1 suggesting that GAG and type I 
collagen production was minimally affected. 
Many of the studies evaluating the effect of TGFβ1 on collagen production have 
utilized mRNA techniques or semi-quantification based on 
immunohistochemistry.8,9,22,35,37  In this study we used a biochemical assay to quantify 
the amount of type I and II produced.  It is possible that small quantities of type II 
collagen were present beneath the detectable threshold.  Limitations of the technique can 
cause underestimation of type II collagen including incomplete cyanogen bromide 
digestion and decreased relative sensitivity of type II compared to type I collagen.   
Although these results are not entirely consistent with the literature, studies are 
extremely difficult to compare.  Similarities between papers include cell type, harvest 
method, basic techniques such as pipetting and cell passage, and the physical monolayer 
environment.  Additionally, the use of pellet culture for 3-dimensional studies is 
common.  However, medium additives, individual characteristics, and species differences 
cause variation in outcome.  In addition, there is large variation between individuals.15  
Although comparing the effects of growth factors within a species would arguably be 
more consistent, studies using canine chondrocyte cultures are uncommon.   
Under the culture conditions described here, TGFβ1 increases the size and GAG 
content of matrix produced by chondrocytes.  Additionally, FGF2 in monolayer is 
mitogenic, but negatively influences matrix formation in 3-dimensions.  However, FGF2 
and TGFβ1, individually or in succession, did not promote collagen type II deposition.   
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Figure 1.  Gross appearance of  pellets after 3 weeks in culture with pellets receiving 
FGF2 in monolayer A and without pretreatment B.  Marks represent 1mm spaces.  Pellets 
labeled by 3-dimensional treatment. 
 
Figure 2.  Chondrocyte pellet histopathology stained with hematoxylin and eosin after 3 
weeks in culture.  All pictures are at 40X magnification.  Yellow bar represents 200 μm. 
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Figure 3.  Chondrocyte pellet histopathology stained with safranin O and fast green after 
3 weeks in culture.  All pictures are at 40X magnification.  Yellow bar represents 200 
μm. 
 
TGF-β1 in 
pellet culture 
FGF-2 in 
pellet culture 
Serum free 
pellet culture 
Serum in 
pellet culture 
Monolayer 
FGF-2 
No FGF-2 
monolayer 
 
 
 66 
CHAPTER 5.  CONCLUSION 
 
SUMMARY 
 This dissertation focuses on clinical outcome measures and articular cartilage 
tissue engineering for the treatment of OA.  In the first study, radiographic evidence of 
OA was compared to limb function.  The results show no correlation between the degree 
of radiographic OA and ground reaction forces produced by dogs diagnosed with OA.  
Additionally, there was no difference from day to day in ground reaction forces.  Despite 
wide spread use, radiographic OA is not correlated with clinical outcome based on limb 
function. 
 Osteoarthritis treatment research is focused on a regenerative medicine paradigm.  
Tissue engineering is one aspect of this philosophy.  The 2nd study in this dissertation is 
focused on using a novel material as a scaffold for cartilage growth.  Using chondrocytes, 
tantalum trabecular metal was a chondroconductive scaffold supporting matrix that was 
84% collagen type II. 
 In order to improve the efficiency and quality of tissue engineered cartilage, 
growth factors were tested on canine chondrocytes in monolayer followed by 3-
dimensional pellet cultures.  Fibroblastic growth factor 2 was mitogenic as predicted; 
however, after 3 weeks of pellet culture, those cells that were treated in monolayer with 
FGF2 contained less collagen and overall matrix than those not pretreated.  Both 
monolayer groups treated with TGFβ1 in pellet culture contained more matrix than any 
other group.  Although disappointing, collagen type I and II quantification showed a 
predominance of type I collagen when using TGFβ1 in pellet culture. 
 
DISCUSSION 
 Clearly, the medium used to grow cartilage in vitro has not been optimized.  
Differences are abundant between species, cell type, and individuals.1,2  This is 
accentuated in cells from older patients or those with OA.2  If this technology is to be 
used on a large scale for a clinical treatment, a predictable and repeatable result is 
necessary.  There are several research directions feasible to overcome this problem 
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including banking select donor cells used for allograft development or optimizing 
conditions for the specific cells harvested.  
 Additionally, the presence and type of scaffold is important.  Scaffold mechanical 
properties effect short and long term matrix properties.3  Interactions between the 
scaffold and chondrocytes influence matrix production and response to growth factors.4  
Although the pellet culture model used in the medium optimization study is widely used, 
it may not reflect the chondrocytic response to the same growth factors when cultured 
with tantalum in a dynamic environment.   
 In chapter 2, chondrocytes were cultured with tantalum producing matrix with 
concentrations of type II collagen that approach normal articular cartilage.  The pellet 
cultures did not have detectible amounts of type II collagen.  However, the 2 studies 
cannot be directly compared because differences in culture environment are abundant.  
Besides the dynamic environment and presence of a scaffold, the chondrocytes seeded on 
the tantalum trabecular metal were exposed to serum throughout the culture process.  
Multiple unknown signaling molecules were present in the serum affecting the cells.  
Defining an efficient serum-free mitogenic and matrix forming medium for optimal 
cartilage growth is necessary for a commercial implant production. 
 An alternative to defining matrix growth medium is to use the patient as an in 
vivo bioreactor.  A scaffold is loaded with cells and implanted into the defect with limited 
time in vitro.  There has been some short-term success with this approach in animals.5  
One potential benefit of using tantalum trabecular metal is the biomechanical properties 
are similar to cancellous bone and can withstand immediate load bearing in vivo.  
Tantalum as a scaffold may protect neocartilage through maturation promoting cartilage 
formation with appropriate biomechanical properties. 
 After defining the appropriate culture conditions, evaluation of the neocartilage 
under load bearing conditions is necessary.  In vivo trials in tissue engineering have 
traditionally looked at the histopathologic, biochemical, and to a lesser extent 
biomechanical properties of repair tissues.  Although valuable, traditional measures of 
therapeutic success do not address the main goals of treatment: decreased pain and 
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increased function.  In future studies, clinical measures of success like gait analysis 
should be used to determine outcome in addition to the traditional measures.   
This dissertation addresses both clinical and basic science aspects of research into 
OA.  The future of OA research lies in integrating the knowledge of several fields into 
clinically applicable treatment options.  Although a cure for OA may seam unfeasible, the 
current tissue engineering research paradigm shows promise. 
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